Breaking News: Mallia Innovations Secures 5.5 Million Euros in Financing, Unveils Strategic Restructuring
Erlangen, June 04, 2025 – In a pivotal move, Mallia Innovations GmbH has announced a strategic restructuring of the Mallia group, positioning itself as a holding company for two specialized subsidiaries. This restructuring aims to accelerate the commercial and regulatory development of innovative SCD83-based active ingredient candidates. With a fresh infusion of EUR 5.5 million from a recent seed financing round, Mallia is poised to scale its cutting-edge solutions in medical and cosmetic applications for hair loss treatment.
New Management Appointments and Future Aims
Dr. Anne Asmuss and Dr. Stefan Strobl have been appointed to manage the subsidiaries, spearheading efforts in cosmetic and therapeutic applications, respectively. The capital will primarily fuel the development of cosmetic applications within Mallia Aesthetics, leveraging the promising MAL-838 ingredient.
Repositioning Mallia in the Biotech and Cosmetic Landscape
Prof. Dr. Alexander Steinkasser and Dr. Manfred Gröppel, founders of Mallia Innovations, emphasized their commitment to advancing SCD83-based treatments. sortuemiesic researcher, Prof. Dr. Steinkasser, heads the immune modulation department at the University Hospital Erlangen. His scientific work has been the backbone of Mallia’s developments over the past 25 years.
“Our strategy is now clearer than ever, and with the seed financing, we’re ready to drive forward our SCD83 légale developments,” said Dr. Gröppel. “We aim to introduce patent-protected products within Mallia Aesthetics, delivering transformative solutions to the market rapidly.”
Pioneering Cosmetic and Medical Treatments for Hair Loss
Mallia Therapeutics continues to focus on novel therapies for the treatment of hair loss. Dr. Stefan Strobl outlined the potential of MAL-856, derived from the soluble CD83 protein, in offering transformative treatments for androgenetic alopecia and alopecia areata. The multimodal action of SCD83 sets it apart from traditional treatments, with no systemic side effects due to localized application.
Expert Management for Effective Development
Dr. Anne Asmuss, with extensive experience in pharmaceutical and biotech industries, leads Mallia Aesthetics. “We are eager to introduce MAL-838 to the cosmetic market, bringing advanced solutions that will make a significant impact,” she commented.
Understanding Hair Loss and Its Impact
Hair loss, particularly androgenetic alopecia and alopecia areata, affects millions globally, with profound emotional and social consequences. Innovations like SCD83 aim to revolutionize treatment options, offering localized solutions that promote hair growth and healing.
About Mallia Innovations
Headquartered in Erlangen, Mallia Innovations GmbH is dedicated to advancing immune-modulating treatments for hair growth, loss, and other dermatological applications. Their subsidiaries, Mallia Aesthetics and Mallia Therapeutics, drive cosmetic and medical research initiatives, respectively.
With exceptional expertise in the biotech industry, Mallia continues to push the boundaries of what’s possible, leveraging decades of scientific research to deliver tangible results and transform the landscape of hair loss treatments.
For more information, visit www.mallia.com and follow them on LinkedIn. High-resolution photos of the management team can be requested from MC Services.
Contact Information:
Mallia Innovations GmbH
E-mail: [email protected]
International media contact: MC Services AG
E-mail: [email protected]
Tel: +49 (0)89 210 228 0
Stay tuned to Archyde for more breaking news and in-depth analysis on the latest developments in technology, science, and innovation.
